Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05374109
Other study ID # Pro00109309
Secondary ID 1R01MH124476-01A
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date January 31, 2026

Study information

Verified date December 2023
Source Duke University
Contact Stuart T Carr, BA
Phone 919 668-4849
Email stuart.carr@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objectives of this proposal are to support positive coping strategies that bolster mental health and lead to improved HIV outcomes among Young People Living with HIV (YPLWH). The central hypothesis is that SYV (Sauti ya Vijana, The Voice of Youth) will be effective to improve antiretroviral therapy (ART) adherence and virologic suppression in YPLWH in Tanzania. The rationale for this project is that by targeting mental health, which is strongly associated with medication adherence, that this will effectively improve adherence and thereby HIV viral suppression. The central hypothesis will be tested in three aims in a hybrid type-1 effectiveness-implementation trial.


Description:

The rigorous experimental design includes a pilot study followed by a parallel-arm randomized control trial (RCT). The pilot will include approximately eight consenting members of the youth community advisory board (CAB) at each site location prior to the RCT. If a youth CAB does not currently exist at each site, one will be formed. Although the investigators have strong pilot data for the SYV intervention from Moshi, the pilot test proposed herein will help ensure recruitment, enrollment, intervention delivery, supervision, measurement technology and logistics run as expected at each site (Moshi, Mbeya, Mwanza, Ifakara). The pilot study will be comprised of 8 participants recruited at each site. Subsequently, for the RCT, we will individually randomize up to 750 participants to receive the SYV intervention or SOC (standard of care) to achieve 90% power to detect a 10 percentage point difference between arms in the primary outcome of virologic suppression at the two-tailed 5% significance level, accounting for clustering by SYV group in the intervention arm. The intervention will be rolled out across four main sites, in four different Tanzanian regions, and in four waves separated in time by 6 months. There will be two SYV groups per wave at each site (~8 groups per site) A study visit for all participants will be conducted baseline and approximately 4 months (T1), 6-, 12-, and 18-months post-baseline (T2, T3, T4) with 6-months post baseline being the primary endpoint. At 12 months post-baseline (T3), those randomized to the SYV intervention will receive a one-session SYV booster to improve content retention and study engagement as has been shown in prior studies.


Recruitment information / eligibility

Status Recruiting
Enrollment 750
Est. completion date January 31, 2026
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 10 Years to 24 Years
Eligibility Inclusion Criteria: - Youth between the ages of 10 and 24 years of age - Attending the enrolling adolescent HIV clinic - Are fully disclosed and aware of their HIV status - Receiving ART for a minimum of 6 months - If = 18 years, able to understand the project and provide written informed consent - If <18 years, a parent or guardian must provide written permission and participant must be able to assent - All adolescents must also commit to attending the 10 weekly SYV sessions and 2 individual sessions Exclusion Criteria: - Active psychosis - Developmental delay, or cognitive disability that precludes active participation in consent process, intervention, and assessment interviews

Study Design


Intervention

Behavioral:
SYV: Sauti ya Vijana (The Voice of Youth intervention)
Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.

Locations

Country Name City State
Tanzania Chronic Disease Clinic of Ifakara Health Institute Ifakara
Tanzania Baylor College of Medicine Children's Foundation - Tanzania, Mbeya Centre for Excellence Mbeya
Tanzania Kilimanjaro Christian Medical Centre Moshi
Tanzania Mawenzi Regional Referral Hospital Moshi
Tanzania Baylor College of Medicine Children's Foundation - Tanzania, Mwanza Centre for Excellence Mwanza
Tanzania Bugando Medical Centre Mwanza

Sponsors (4)

Lead Sponsor Collaborator
Duke University Kilimanjaro Christian Medical Centre, Tanzania, National Institute for Medical Research, Tanzania, National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Tanzania, 

References & Publications (2)

Dow DE, Mmbaga BT, Gallis JA, Turner EL, Gandhi M, Cunningham CK, O'Donnell KE. A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. BMC Public Health. 2020 Sep 4;20(1):1358. doi: 10.1186/s12889-020-09380-3. — View Citation

Dow DE, Mmbaga BT, Turner EL, Gallis JA, Tabb ZJ, Cunningham CK, O'Donnell KE. Building resilience: a mental health intervention for Tanzanian youth living with HIV. AIDS Care. 2018;30(sup4):12-20. doi: 10.1080/09540121.2018.1527008. Epub 2019 Jan 9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Virologic suppression as measured by percent of patients with a HIV RNA <400 copies/mL HIV RNA measured by blood testing 6 months post-baseline visit
Secondary Change in virologic suppression as measured by percent of patients with a HIV RNA <400 copies/mL HIV RNA measured by blood testing Baseline, months 4, 12 and 18 post-baseline visit
Secondary Change in the percentage of patients who are HIV RNA undetectable (<400 copies m/L) as measured by blood test HIV RNA results Baseline, months 4, 6, 12 and 18 post-baseline visit
Secondary Change in the percentage of patients who are HIV RNA detectable (>400 copies m/L) as measured by blood test HIV RNA results Baseline, months 4, 6, 12 and 18 post-baseline visit
Secondary Change in anti-retroviral therapy (ART) adherence as measured by SYV (Sauti ya Vijana) Scale - Adherence section SYV Scale - Adherence section (Likert scale - not applicable) Baseline, months 4, 6, 12 and 18 post-baseline visit
Secondary Change in anti-retroviral therapy (ART) adherence as measured by concentration of ART medication(s) in hair sample hair samples sent for analysis Baseline, months 4, 6, 12 and 18 post-baseline visit
Secondary Change in mental health status as measured by SYV Scale - General Anxiety Disorder-7 (GAD-7) section SYV Scale - General Anxiety Disorder-7 (GAD-7) section (Likert scale 0 not at all to 3 nearly every day) 0 is the most positive choice Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in mental health status as measured by SYV Scale - Patient Health Questionnaire-9 (PHQ-9) section SYV Scale - Patient Health Questionnaire-9 (PHQ-9) section (Likert scale 0 not at all to 3 nearly every day) 0 is the most positive choice Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in mental health status as measured by SYV Scale - Strengths and Difficulties Questionnaire (SDQ) section SYV Scale - Strengths and Difficulties Questionnaire (SDQ) section (Likert scale 0 never true of me to 2 usually true of me) 0 or 2 can be most positive or most negative choices depending on the question Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in mental health status as measured by SYV Scale - Self-Esteem section SYV Scale - Self-Esteem section (Likert scale - 4 options from strongly agree to strongly disagree - no choice is most positive) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in mental health status as measured by SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section (Likert scale - 5 options from Always to Never - Always is the most positive choice, 5 options Many Times, A few times, Once, Never or Refused - Never is the most positive choice, 4 options None, Little, Much and Most - no choice is the most positive and 3 options are Yes, No or Not Sure - No is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in coping habits as measured by SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section SYV Scale - Adverse Childhood Experiences International Questionnaire (ACE-IQ) section (Likert scale - 5 options from Always to Never - Never is the most positive choice, 5 options Many Times, A few times, Once, Never or Refused - Never is the most positive choice, 4 options None, Little, Much and Most - no choice is most positive and 3 options are Yes, No or Not Sure - No is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in resilience as measured by SYV Scale - Adapted People Living with HIV Resilience Scale SYV Scale - Adapted People Living with HIV Resilience Scale (Likert scale 5 options from strongly disagree to strongly agree - strongly agree is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in stigma as measured by SYV Scale - Stigma section SYV Scale - Stigma section (Likert scale 1 strongly disagree to 4 strongly agree - no most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in overall quality of life measured by SYV Scale - Quality of Life (QOL) SYV Scale - Quality of Life (QOL) (Likert scale 5 options from very poor/very dissatisfied to very good/very satisfied - very good/very satisfied is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in gender based violence as measured by SYV Scale - Violence against partner section SYV Scale - Violence against partner section (Likert scale Yes or No - No is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in gender based violence as measured by SYV Scale - Violence Perpetration section SYV Scale - Violence Perpetration section (Likert scale Yes or No - No is the most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in disclosure as measured by SYV Scale - Stigma section SYV Scale - Stigma section (Likert scale 1 strongly disagree to 4 strongly agree - strongly disagree is the most positive choice) and Sexual section (Likert scale - N/A) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in HIV knowledge as measured by SYV Scale - HIV Knowledge Questionnaire-18 (HIV-KQ-18) section SYV Scale - HIV Knowledge Questionnaire-18 (HIV-KQ-18) section (Likert scale True/False/I don't know - no most positive choice) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in sexual high-risk behaviors as measured by SYV Scale - Sexual section SYV Scale - Sexual section (Likert scale - N/A) Baseline, 4, 6, 12 and 18 months post-baseline visit
Secondary Change in substance abuse high-risk behaviors as measured by SYV Scale - Personal section SYV Scale - Personal section (Likert scale N/A) Baseline, 4, 6, 12 and 18 months post-baseline visit
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Completed NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4